Page last updated: 2024-09-05

erlotinib and canertinib dihydrochloride

erlotinib has been researched along with canertinib dihydrochloride in 2 studies

Compound Research Comparison

Studies (erlotinib)	Trials (erlotinib)	Recent Studies (post-2010) (erlotinib)	Studies (canertinib dihydrochloride)	Trials (canertinib dihydrochloride)	Recent Studies (post-2010) (canertinib dihydrochloride)
221	0	180	31	13	6

Protein Interaction Comparison

Protein	Taxonomy	canertinib dihydrochloride (IC50)
Epidermal growth factor receptor	Homo sapiens (human)	0.0036
Receptor tyrosine-protein kinase erbB-2	Homo sapiens (human)	0.0132
Receptor tyrosine-protein kinase erbB-4	Homo sapiens (human)	0.029

Research

Studies (2)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (50.00)	29.6817
2010's	1 (50.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Althaus, IW; Amato, DM; Bridges, AJ; Denny, WA; Elliott, WL; Ellis, PA; Fry, DW; Gonzales, AJ; Han, HK; Harvey, PJ; Klutchko, SR; Meade, MA; Nelson, JM; Pace, G; Roberts, BJ; Sherwood, V; Showalter, HD; Smaill, JB; Tran, TP; Winters, RT; Zhou, H	1
Russu, WA; Shallal, HM	1

Other Studies

2 other study(ies) available for erlotinib and canertinib dihydrochloride

Article	Year
Tyrosine kinase inhibitors. 19. 6-Alkynamides of 4-anilinoquinazolines and 4-anilinopyrido[3,4-d]pyrimidines as irreversible inhibitors of the erbB family of tyrosine kinase receptors. Journal of medicinal chemistry, 2006, Feb-23, Volume: 49, Issue:4 Topics: Alkynes; Amides; Aniline Compounds; Animals; Antineoplastic Agents; Cell Line; Dogs; ErbB Receptors; Haplorhini; Humans; Mice; Mice, Nude; Mice, SCID; Phosphorylation; Pyrimidines; Quinazolines; Rats; Receptor Protein-Tyrosine Kinases; Receptor, ErbB-2; Receptor, ErbB-4; Structure-Activity Relationship; Xenograft Model Antitumor Assays	2006
Discovery, synthesis, and investigation of the antitumor activity of novel piperazinylpyrimidine derivatives. European journal of medicinal chemistry, 2011, Volume: 46, Issue:6 Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Discovery; Drug Screening Assays, Antitumor; Humans; Models, Molecular; Molecular Structure; Piperazines; Protein Kinase Inhibitors; Protein Kinases; Pyrimidines; Stereoisomerism; Structure-Activity Relationship	2011

Article

Year

Tyrosine kinase inhibitors. 19. 6-Alkynamides of 4-anilinoquinazolines and 4-anilinopyrido[3,4-d]pyrimidines as irreversible inhibitors of the erbB family of tyrosine kinase receptors.

Journal of medicinal chemistry, 2006, Feb-23, Volume: 49, Issue:4

Topics: Alkynes; Amides; Aniline Compounds; Animals; Antineoplastic Agents; Cell Line; Dogs; ErbB Receptors; Haplorhini; Humans; Mice; Mice, Nude; Mice, SCID; Phosphorylation; Pyrimidines; Quinazolines; Rats; Receptor Protein-Tyrosine Kinases; Receptor, ErbB-2; Receptor, ErbB-4; Structure-Activity Relationship; Xenograft Model Antitumor Assays

2006

Discovery, synthesis, and investigation of the antitumor activity of novel piperazinylpyrimidine derivatives.

European journal of medicinal chemistry, 2011, Volume: 46, Issue:6

Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Discovery; Drug Screening Assays, Antitumor; Humans; Models, Molecular; Molecular Structure; Piperazines; Protein Kinase Inhibitors; Protein Kinases; Pyrimidines; Stereoisomerism; Structure-Activity Relationship

2011